Boston Scientific to Participate in 30th Annual J.P. Morgan Healthcare Conference
This will be a key presentaion with the CEO, President and CFO in attendance and should highlight the EPS gains due to cost cutting and gains from JNJ discontinuing competing products and termination of royalty payments to ABT.
This may result in $500-600 million of additional earnings boost a year going forward, or 33-39 cents a share more.
not only more upgrades, but we should be back to at least $10 by the meeting, since earnings for all major companies will be announced by then, and BSX's expected double digit growth and continued market share gains over MDT, STJ, ABT, and JNJ will further cement BSX's upward trajectory. With the FDA news about them stopping JNJ's meshes, this is another market share gain for BSX since JNJ is exiting the mesh industry.